Matthew V. Lorenzi - Department of Discovery Biology, Bristol-Myers Squibb Pharmaceutical Research Institute

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 118 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Text from Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Smruthi Vijayaraghavan,Lorraine Lipfert,Kristen Chevalier,Barbara S. Bushey,Benjamin Henley,Ryan Lenhart,Jocelyn Sendecki,Marilda Beqiri,Hillary J. Millar,Kathryn Packman,Matthew V. Lorenzi,Sylvie Laquerre,Sheri L. Moores

openalex（2023）

Cited0Views0Bibtex

Supplementary Table S1-S2 and Figure S1-S2 from Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Jayaprakash D. Karkera,Gabriela Martinez Cardona,Katherine Bell,Dana Gaffney, Joseph C. Portale,Ademi Santiago-Walker, Christopher H. Moy, Peter King,Michael Sharp,Rastislav Bahleda, Feng R. Luo,John D. Alvarez,Matthew V. Lorenzi,Suso J. Platero

openalex（2023）

Cited0Views0Bibtex

Supplementary Movie M2 from Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn